Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

42.53 -0.10 (-0.23%)
Streaming Delayed Price Updated: 1:20 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Where Xenon Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022 ↗
 
Via Benzinga
News headline image
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For November 8, 2022 ↗
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million. 
Via Benzinga
News headline image
Analyst Sees This Epilepsy Player As 'M&A Sweet Spot' ↗
 
Via Benzinga
News headline image
Earnings Preview: Xenon Pharmaceuticals ↗
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon... 
Via Benzinga
News headline image
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends. ↗
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends. 
Via InvestorPlace
News headline image
Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
News headline image
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says ↗
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Analyst Ratings for Xenon Pharmaceuticals ↗
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
4 Analysts Have This to Say About Xenon Pharmaceuticals ↗
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
News headline image
4 Analysts Have This to Say About Xenon Pharmaceuticals ↗
  Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals ↗
  Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter: 
Via Benzinga
News headline image
Xenon Pharmaceuticals: Q2 Earnings Insights ↗
  Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Outlook For Xenon Pharmaceuticals ↗
  Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency ↗
 
Via Benzinga
News headline image
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering ↗
 
Via Benzinga
News headline image
Recap: Xenon Pharmaceuticals Q1 Earnings ↗
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2022 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All ↗
The company had bullish results in seizure treatment. But it wasn't enough. 
Via Investor's Business Daily
News headline image
US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony ↗
Pre-open movers 
Via Benzinga
News headline image
Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
News headline image
Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For May 10, 2022 ↗
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.